Intermede Investment Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Colgate-Palmolive
CL
|
+$44.5M |
| 2 |
Televisa
TV
|
+$31.7M |
| 3 |
Zoetis
ZTS
|
+$13.8M |
| 4 |
S&P Global
SPGI
|
+$11.9M |
| 5 |
Oracle
ORCL
|
+$9.85M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$52M |
| 2 |
TJX Companies
TJX
|
+$8.92M |
| 3 |
HDFC Bank
HDB
|
+$4.55M |
| 4 |
Alibaba
BABA
|
+$2.56M |
| 5 |
CME Group
CME
|
+$2.15M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 24.49% |
| 2 | Communication Services | 19.22% |
| 3 | Healthcare | 17.95% |
| 4 | Technology | 16.84% |
| 5 | Consumer Discretionary | 9.08% |
Similar funds
Intermede Investment Partners's Q2 2018 Portfolio in Review
As of Q2 2018, Intermede Investment Partners held 28 positions worth $1.26B, up 8.5% from $1.16B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Intermede Investment Partners deployed $55.5M of net new capital in Q2 2018, opening 3 new positions and adding to 10 existing holdings. Its largest new stake was Colgate-Palmolive: 680,959 shares worth $44.1M.
By sector, the portfolio is most concentrated in Financials at 24% of assets, down from 25% a quarter earlier, followed by Communication Services and Healthcare.
On the sell side, the largest reduction was TJX Companies, an estimated $8.92M trimmed.
- Intermede Investment Partners's largest Q2 2018 buy was Colgate-Palmolive: 680,959 shares worth $44.1M.
- Intermede Investment Partners added most to Zoetis in Q2 2018, an estimated $13.8M increase.
- Intermede Investment Partners's biggest Q2 2018 reduction was TJX Companies, cutting an estimated $8.92M.
- Intermede Investment Partners fully exited Medtronic in Q2 2018, selling an estimated $52M.
- Intermede Investment Partners's ten largest holdings make up 51% of its $1.26B portfolio in Q2 2018.
- Intermede Investment Partners opened 3 new positions and closed 1 in Q2 2018.
- Intermede Investment Partners's portfolio value rose 8.5% quarter-over-quarter to $1.26B.
Based on Intermede Investment Partners's 13F filing for Q2 2018, filed 8 Aug 2018.